NEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Strainsforpains, Inc., fka/ E-Buy Home Inc., (OTC:EBYH) an emerging cannabinoid-based retail and wholesale drug commercialization specialist is very pleased to announce that it has just signed an international retail and wholesale cannabinoid drug commercialization agreement with Cannabis Science, Inc Strainsforpains, Inc., President & CEO., Mr. Simon Shainberg stated, "Cannabis Science is best known for it's Harvard Award Winning Cancer Killing Success. Cannabis Science has a robust pipeline of therapeutic and critical ailment cannabinoid drugs to be released. To start, Strainsforpains has successfully released a proven cannabinoid-based product pipeline and we have garnered excellent sales growth in a short period of time. The Cannabis Science CBN US Patent protected product pipeline is exciting for instant market penetration targeting sleep deprivation as well as targeting PTSD and other neurological conditions. The Harvard Award winning cancer killing success and the Cannabis Science Cancer drug pipeline is an automatic success magnet if you throw a little money at it to commercialize it through the FDA and other jurisdictional regulatory bodies to bring to market." CSi-CBN Patent: "Composition for Treatment of Neurobehavioral Disorders" Protections and Product Release, Sleep, PTSD, Neurological Conditions. US Patent number US10413578. CBN Sleep Products for Sleep Deprivation, PTSD, OCD, ADHD and more. The Sleep deprivation and PTSD markets combined are well over $500 Billion Worldwide with a shortage of cost effect treatments and therapies. Leaving the opportunity to fulfill this demand a major windfall. patents.google.com/patent/US10413578B2/en Mr. Shainberg confirms again, "The introduction of diversified cannabinoid-based products, coupled with strategic partnerships with hemp farmers in Virginia and Pennsylvania, positions the company for rapid growth in 2024. We are proud to have established strong partnerships ensuring a resilient and optimized supply chain, with products stored both at our 7-acre Pennsylvania facility and our New York City locations. Has initial orders, comprising over 3000 units of CBD body cream, is set to be distributed across pharmacies and wellness centers in the Tri State area. Notable locations include Central Pharmacy of Brooklyn, DIV Pharmacy of Flatbush, Kyse Pharmacy of Rockaway, and other reputable dispensaries and health centers throughout New York. With the $65,000 order in the last quarter of 2023 and the $130,000 order in early 2024, we are well-positioned to surpass our initial projections of $500,000 in sales for 2024. The positive responses from stores, dispensaries and customers have fueled our determination to diversify our CBD product line into other CBD products later in 2024." Cannabis Science HARVARD Award Winning Cancer Killing Drug Development. The Top CSi-Cancer Killing Drug Valuation targets are ready for Clinical Trials, Pharmacokinetics, and FDA IND# application: Stage 4 Lung CancerPancreatic CancerStage 4 Breast CancerBasil Cell Carcinoma (Skin Cancer)Brain CancerKaposi's Sarcoma